Effect of fluvoxamine on the pharmokinetics of zolpidem: A two-treatment period study in healthy volunteers

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 1, 2012, Pages 9-12

  Vlase, Laurian ^a   Popa, Adina ^a   Neag, Maria ^b   Muntean, Dana ^a   Achim, Marcela ^a   Leucuţa, Sorin Emilian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug interaction; Fluvoxamine; Pharmacokinetics; Zolpidem

Indexed keywords

FLUVOXAMINE; ZOLPIDEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG INTERACTIONS; FLUVOXAMINE; GABA-A RECEPTOR AGONISTS; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; METABOLIC CLEARANCE RATE; PYRIDINES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84855170546     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05625.x     Document Type: Article

References (22)

1. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 1995; 29: 142-53.
2. Von Moltke LL, Greenblatt DJ, Granda BW et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol. 1999; 48: 89-97.
3. Harrison TS, Keating GM. Zolpidem. A review of its use in the management of Insomnia. CNS Drugs 2005; 19: 65-89.
4. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin. Pharmacol. Ther. 2009; 85: 644-50.
5. Sanofi-Aventis US LLC. Ambiem (zolpidem tartrat) tablets CIV: Prescribing information. (Online); Available from: (accessed 18 August 2011).
6. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br. J. Clin. Pharmacol. 2006; 63: 116-20.
7. Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin. Pharmacol. Ther. 2007; 82: 54-62.
8. Villikka K, Kivistö KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin. Pharmacol. Ther. 1997; 62: 629-34.
9. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997; 32(Suppl. 1): 1-21.
10. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin. Ther. 2008; 30: 1206-27.
11. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 1995; 29(Suppl. 1): 1-9.
12. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. 1998; 34: 281-302.
13. Schuirmann DJ. A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 1987; 15: 657-80.
14. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. July 2002. (online) Available from: (accessed 18 August 2011).
15. The European Agency for the Evaluation of Medicinal Products, Committee for medicinal products for human use. Guideline on the investigation of bioequivalence. London, January 2010. (online) Available from: (accessed 18 August 2011).
16. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. November 1999. (online). Available from: (accessed 18 August 2011).
17. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Draft guidance. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. September 2006. (online) Available from: (accessed 18 August 2011).
18. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002; 54: 1271-94.
19. Neve EPA, Ingelman-Sundberg M. Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum. Curr. Opin. Drug Discov. Devel. 2010; 13: 78-85.
20. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol. 2000; 23: 54-8.
21. Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: Case reports and a review of the literature. Prim. Care Companion J. Clin. Psychiatry. 2010; 12: PCC.09r00849. Available from:, (accessed 21 September 2011).
22. Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: A possible interaction. Int. Psychogeriatr. 2006; 18: 749-51.